Poolbeg Pharma Share Discussion Threads

[burtond1] 20/9/2023 07:16

Great news for #POLB They received a notice of allowance from @JPO_JPN in relation to the Immunomodulator I patent application related to the use of p38 MAPK inhibitors for the treatment of severe #influenza. Strengthening their intellectual property protection in the territory.https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/w6m9gqx

[joseph moran] 19/9/2023 13:05

I just bought a few and it is showing as a sell, so a lot of the sells will be buys.

[baldrick1] 19/9/2023 12:55

That was a relief news mucho ;))

[klosters65] 19/9/2023 12:07

Just a thought. Maybe a deal can be struck with whoever was trying to do the blocking.I notice, it was settled amicably.

[muchodinero] 19/9/2023 10:51

We can assume it was a big pharmaceutical company trying unsuccessfully to block our patent? Looking more positive now this roadblock has been removed from potential deals being signed?

[troutisout] 19/9/2023 10:08

Just had a top up at under 7p, I think this will lose the malaise surrounding Investor here soon and the potential will come to the fore.
Trout.

[troutisout] 19/9/2023 09:36

Tend to agree....No one would have signed an agreement with that hanging over it. A resolution is very positive.

[adorling] 19/9/2023 08:57

Expect a big partnering deal for #POLB001 in the next few months. This Patent resolution was holding any deal up being concluded. It is now sorted.

[burtond1] 19/9/2023 08:07

Re todays news...This is a very favorable resolution and a very positive outcome for Poolbeg, who have full confidence in the strength and validity of their patent portfolio and looks like will continue to broaden and defend their intellectual property going forward.https://www.londonstockexchange.com/news-article/POLB/immunomodulator-i-patent-opposition-withdrawal/16129437

[klosters65] 15/9/2023 23:45

Thanks elrico, Just wish the share price would respond correspondingly. The share price has swung 2 to 3 times from 7p to 9p and each time I have resisted in unloading a few, (and I have many ). By holding on, I would like to be fully rewarded next time on an upward move please.

[elrico] 15/9/2023 20:00

🎉 #POLB
@PoolbegPharma
H1 2023 Highlights 🎉

💰 Maintaining a strong financial backbone with a cash balance of £14.1M
🔬 Positive outcomes in the POLB 001 LPS human trial, showcasing potential in treating severe influenza & other inflammatory conditions
📈 Exploring strategic expansions of POLB 001 into oncology & new indications beyond CAR T
🤖 Leveraging AI with CytoReason for groundbreaking insights into influenza & identifying novel drug targets 🔎 Progressing steadily with lab validations and poised for vital completions in H2 2023 & H1 2024
🌐 Moving forward in the EncOVac project with a fresh €2.3M grant
🌟 Welcoming industry veteran Professor Brendan Buckley to the board
#HealthTech #PharmaNews #BusinessUpdate #InnovationInHealthcare
[...]

[burtond1] 15/9/2023 07:32

You can access #research notes directly on the Poolbeg Pharma website.Read the research notes by @CavendishCF, @_singercm and @proactive_UK through @research_tree ?Access here ??:https://www.poolbegpharma.com/investors/analyst-research/

[troutisout] 13/9/2023 10:45

No point in finishing it in 2023 if it won't show what it needs to, these things always evolve and take longer, still a long way to go with this and they need to get it right, to make it valuable to someone to license/acquire.

[melody9999] 13/9/2023 09:15

Continued progress on the Oral GLP-1 agonist proof-of-technology clinical trial preparation. As a result of adopting recommendations from a number of Key Opinion Leaders (KOLs), the clinical trial design has been refined and the trial is expected to commence in H1 2024

On 020323 they announced the trial outcome was due Q4 2023. Now it won't commence until H1 2024 ????

[burtond1] 13/9/2023 07:36

Cracking results for #POLB "...With a low operational burn and strong financial discipline, we ended the period with a robust financial position of £14.1m cash...."Cathal FrielChairman and Co-Founderhttps://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/x2el0lx

[burtond1] 07/9/2023 09:46

@EncOVac_ is developing a platform for the #encapsulation of vaccines for a wide range of infectious diseases, representing a significant commercial opportunity.Learn more about the programmes & the strong expertise behind the technology here:https://www.poolbegpharma.com/pipeline/oral-vaccine-platform/

[burtond1] 06/9/2023 12:01

The #POLB CEO runs through all the latest slides with @DirectorsTalk on their cutting-edge #AI programmes in #RSV & #Influenza?Industry leading human challenge trial data powered AI drug discovery?Successfully identified novel drug targets & treatmentshttps://www.directorstalkinterviews.com/poolbeg-pharma-a.i.unlocking-the-power-of-unique-human-challenge-trial-data/4121126617

[burtond1] 30/8/2023 09:31

Learn more about the impact of climate change on the spread of #infectiousdisease and how #POLB could make a difference. Explore how climate change reshapes disease dynamics and poses a threat to #globalhealth https://www.linkedin.com/pulse/impact-climate-change-infectious-diseases-global-health?utm_source=share&utm_medium=member_ios&utm_campaign=share_via

[burtond1] 29/8/2023 08:09

Worth a watch...Please see link to interview posted this morning by Dr Paula Maguire outlining her experience and what she's so excited about with Poolbeg.https://twitter.com/PoolbegPharma/status/1696408721143071101?s=20

[klosters65] 24/8/2023 12:03

I am sure our patience will be rewarded one day. However, in the meantime, it is the most irritating of shares.

[inaminute] 23/8/2023 12:20

https://x.com/poolbegpharma/status/1694227973317013590?s=46

[burtond1] 21/8/2023 12:20

Great news for #POLB They are delighted to have been shortlisted to the final round in the Best Emerging #Biotech Company category of the 2023 #OBN Awards, designed to celebrate innovation & achievement across the #LifeSciences sector.See finalists here:https://obn.glueup.com/event/obn-awards-2023-74448/2023-finalists.html

[chica1] 17/8/2023 14:04

The 2 meanings of the word 'lemming'

1 A rodent similar to a 🐀
2.Uniformed morons who sign up to a 🐀 for investment advice without doing their own due diligence.

[elrico] 16/8/2023 23:27

The Licensing-out is what we investors are waiting for. By way of an apology for my earlier outburst, after seeing my name in a post of klosters trigger the usual suspect, I thought I would try to make amends and bend the knee a little. :)

It is worth revisiting the investor deck. I have focused on the licensing-out model because we investors are eager to see news for that.

Poolbeg's Licensing-out
Lead asset POLB 001 has shown promise as an immunomodulator for severe influenza; the company is well-positioned to license out its technology to larger pharmaceutical corporations. Talks are ongoing!

Benefits to Poolbeg (Commercialisation)
Licensing allows Poolbeg to generate immediate revenue without the extensive costs and time associated with bringing a drug to market. This revenue often comes in the form of upfront payments, milestone payments based on developmental progress, and royalties from sales.

Risk Mitigation
By licensing out its technology, Poolbeg can transfer some of the risks associated with drug development, regulatory approvals, and market uncertainties to the licensee.

Resource Allocation
Licensing enables Poolbeg to allocate its resources more efficiently. Instead of investing heavily in late-stage trials or global market penetration, the company can focus on its core strength: early-stage research and development.

Benefits to Licensees (Big Pharma)
Access to Innovative Solutions: Licensing allows pharmaceutical giants to access and benefit from Poolbeg's innovative treatments without investing years in research.

Faster Time-to-Market
With a licensed product, pharmaceutical corporations can reduce the time it takes to introduce a new drug, especially if the product has already undergone initial trials.

Diversification
For big pharma, licensing is a way to diversify their product portfolio, ensuring they have a mix of products at different stages of development.

The Potential of POLB 001
Given the significant unmet need in the influenza market, the licensing potential of POLB 001 is vast. Severe influenza has an economic burden of approximately $11 billion in the US alone. With no suitable drug currently on the market for the 3-5 million severe influenza cases reported globally, the licensing value of POLB 001 could be monumental.

Poolbeg's licensing model is a testament to the company's forward-thinking approach. By leveraging its research prowess and offering innovative solutions to larger pharmaceutical entities, Poolbeg ensures a revenue stream and amplifies its impact in the medical world. For investors and industry stakeholders, this model underscores Poolbeg's strategic insight and its potential for sustained growth.

A cash balance of £16.2m as of December 2022 is a testament to its sound financial management. It provides a multi-year runway before funds rundown, meaning the BOD are not in a vulnerable negotiation position. Moreover, with a portfolio approach that advances multiple programs in parallel, the risk is effectively spread out, ensuring a higher probability of success.

There's plenty of sponsored open-source material at:

[klosters65] 16/8/2023 23:19

Forgive all the ?. I am ancient and do not have a computer, and that is what my mobile does until one of you has the ability to explain to me how to stop this problem.